In the current analysis, we also observed differences between STAD and CRC patients when using MYH11 protein as a prognostic marker, with higher levels of MYH11 in STAD tumours reflecting significantly poorer survival (Figure 6B) and a relatively better survival rate in CRC tumours (Figure 6C). This evidence concerns the gene MYH11 and neoplasm.